Thermo Fisher Scientific Inc. $TMO Shares Sold by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,938 shares of the medical research company’s stock after selling 12,302 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Thermo Fisher Scientific were worth $29,168,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Financial Security Advisor Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter valued at $378,000. Callan Family Office LLC increased its position in shares of Thermo Fisher Scientific by 34.9% during the 2nd quarter. Callan Family Office LLC now owns 16,033 shares of the medical research company’s stock worth $6,501,000 after purchasing an additional 4,146 shares during the last quarter. Court Place Advisors LLC increased its position in shares of Thermo Fisher Scientific by 6.6% during the 2nd quarter. Court Place Advisors LLC now owns 4,941 shares of the medical research company’s stock worth $2,003,000 after purchasing an additional 305 shares during the last quarter. TFR Capital LLC. boosted its stake in Thermo Fisher Scientific by 20.5% during the second quarter. TFR Capital LLC. now owns 1,151 shares of the medical research company’s stock worth $467,000 after buying an additional 196 shares during the period. Finally, Boomfish Wealth Group LLC boosted its stake in Thermo Fisher Scientific by 30.5% during the second quarter. Boomfish Wealth Group LLC now owns 6,026 shares of the medical research company’s stock worth $2,443,000 after buying an additional 1,407 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $534.92 on Friday. The stock’s 50-day moving average is $487.44 and its two-hundred day moving average is $448.31. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a market cap of $201.99 billion, a price-to-earnings ratio of 30.94, a price-to-earnings-growth ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the company posted $5.37 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Activity

In other news, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Barclays lifted their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Finally, HSBC reissued a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $593.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.